CD8A and neoplasm: TYMP is responsible for systemic tumor-specific CD8+ cell exhaustion and abrogates adoptive dendritic cell therapy efficacy in a preclinical CRC model, which depicts systemic T-cell loss and reduced ACT or immunotherapy efficacy observed in animal models with advanced CRC.